Novartis AG to Discuss Entresto® FDA Label Expansion Investor Q&A Call Transcript
Good morning, and good afternoon, and welcome to the Novartis Investor Conference Call on Entresto FDA Label Expansion. (Operator Instructions) The conference is being recorded. (Operator Instructions) A recording of the conference call, including the Q&A session will be available on our website shortly after the call ends. (Operator Instructions)
With that, I would like to hand over to Mr. Samir Shah, Head of Investor Relations. Please go ahead, sir.
Thank you very much, and good morning, and good afternoon to everybody. Big thank you for taking the time to participate in this -- mainly Q&A session or investor call in relation to the Entresto label update.
With us today, we have David Soergel MD, who's the Global Head of the Cardiovascular, Renal and Metabolism Development unit. We also have Rod Wooten, who is the Global Head for Marketing at Novartis Pharmaceuticals. I think many of you will be familiar with both these people who was present at the Novartis management meeting back in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
